Article
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.
Molecular cancer research : MCR - 1 Apr 2021
Gao Sizhi Paul, Kiliti Amber J, Zhang Kai, Vasani Naresh, Mao Ninghui, Jordan Emmet, Wise Hannah C, Shrestha Bhattarai Tripti, Hu Wenhuo, Dorso Madeline, Rodrigues James A, Kim Kwanghee, Hanrahan Aphrothiti J, Razavi Pedram, Carver Brett, Chandarlapaty Sarat, Reis-Filho Jorge S, Taylor Barry S, Solit David B
Abstract excerpt
Mutational activation of the PI3K/AKT pathway is among the most common pro-oncogenic events in human cancers. The clinical utility of PI3K and AKT inhibitors has, however, been modest to date. Here, we used CRISPR-mediated gene editing to study the biological consequences of AKT1 E17K mutation by developing an AKT1 E17K-mutant isogenic system in a TP53-null background. AKT1 E17K expression under the control of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.